Valuation dashboard for Silence Therapeutics plc (SLN) with P/E N/A, P/B 5.00, EV/EBITDA -9.01 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver.
Analysis Summary
Silence Therapeutics plc reported revenue of $559000 in the most recent fiscal year, growing at a 5-year CAGR of -36.7%.
Trailing-twelve-month margins: gross margin 51.0%, operating margin -108.8%, net margin -97.6%.
At the current price of $12.50, SLN has negative trailing earnings (P/E not meaningful) and an ROE of -106.94%. Market capitalisation stands at $590M.
Balance sheet quality for SLN: current ratio of 8.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 5.00 |
| EV / EBITDA | -9.01 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $1.84 |
| vs Current Price | -85.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SLN | Silence Therapeutics plc | $590M | 5.00 | -106.9% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $12.50 |
| Market Cap | $590M |
| Exchange | NASDAQ |
| Country | GB |
Profitability
| Return on Equity | -106.94% |
| Return on Invested Capital | -71.25% |
| Return on Assets | -56.34% |
| Gross Margin | 51.00% |
| Operating Margin | -10880.25% |
| Net Margin | -9759.23% |
Related companies: ACIU · ALDX · AMRN · ANRO · CAPR · CTNM · KYTX
Explore sector: Healthcare · Biotechnology
More sections of SLN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks